Cytokine storm and the prospects for immunotherapy with COVID-19

Posted April 13, 2020

ABSTRACT

Knowledge about the pathobiology of SARS-COV-2 as it interacts with immune defenses is limited. SARS-COV-2 is spread by droplets that come into contact with mucous membranes. COVID-19 is characterized by 3 stages: asymptomatic-paucisymptomatic incubation, nonsevere symptomatic illness for 80% of those infected, and severe respiratory illness. A syndrome characterized by hypercytokinemic inflammation referred to as a “cytokine storm” can occur in patients with advanced disease. Effective antiviral agents that can prevent viral infection in exposed individuals are needed.

As we learn about COVID-19, we recognize that there are gaping holes in our knowledge of the pathobiology of SARS-COV-2 as it interacts with our immune defenses. Epidemiologically, we know that most people, especially young and healthy ones, do quite well at defending themselves from this infection and that those with severe disease tend to recover without sequelae. We also know that not everyone has a relatively benign disease course and that risk factors for progression are dominated by age and comorbidities, especially cardiovascular disease, diabetes, and obesity. While some of these clinical findings seem to have face-validity, others are not so clear. Why is age such a dominant risk factor, and why do some young, otherwise seemingly healthy individuals succumb to the infection? The answers to these questions are not completely understood.

To tackle this problem, we must first examine what is known about the pathogen host immune system interaction. SARS-COV-2 is spread by droplets that come into contact with mucous membranes. Interestingly, not all individuals who are exposed acquire the infection. Once infected, the disease progresses through 3 main stages (Figure 1).

Stage 1 is an asymptomatic-paucisymptomatic incubation period where the virus may or may not be clinically detectable. Stage 2 is a period of nonsevere symptomatic illness with detectable virus that may resolve or progress. In infected individuals, approximately 80% will end in stage 2. Finally, stage 3 is characterized by severe respiratory illness with progressive pneumonitis that may or may not lead to respiratory failure, which in its final stages, causes diffuse alveolar damage. As discussed below, this last stage is characterized by a state of high levels of inflammation leading to further clinical deterioration and potential involvement of extrapulmonic sites such as cardiac tissue.1

Immunologically, SARS-COV-2 infects cells of the respiratory tract and likely infects endothelial cells and macrophages based on our knowledge of SARS-CoV, which shares considerable homology. Infection triggers innate immunity followed by adaptive humoral and cellular immune responses. The
development of neutralizing antibodies is believed to be a critical event in recovery as well as the generation of virus-specific T-cell responses, ultimately leading to viral clearance. Unfortunately, the process is not linear, and we are still trying to understand why adaptive immunity fails and many infected individuals continue to be carriers of the virus.

Attempts to correlate the stages of clinical disease described above with SARS-COV-2 viral loads from respiratory secretions, blood, and tissues have yielded conflicting results: some patients with advanced disease have high viral loads while others do not. Recent attempts to reconcile these findings suggest that cytokine production belies many of the late-stage disease manifestations in COVID-19 disease, and this may be driven by viral infection or noninfective sources such as collateral tissue destruction.

In patients with advancing disease, a syndrome has been reported characterized by hypercytokinemic inflammation. This syndrome has variably been referred to as “cytokine storm,” or at times, as macrophage activation syndrome (MAS) or secondary hemophagocytic lymphohistiocytosis (sHLH). In COVID-19, and unlike MAS or sHLH, the primary target organ is the lung, leading to an acute respiratory distress syndrome with some shared features to the idiopathic form both clinically and pathologically.

Laboratory features are quite similar among these disorders, with marked elevations of acute phase reactants (ie, C-reactive protein, ferritin), lymphopenia, coagulation defects, and elevated levels of numerous inflammatory cytokines; prominent among them are interleukins 6 (IL-6), 1 (IL-1), 2 (IL-2), 7 (IL-7), and 17 (IL-17), granulocyte macrophage-colony stimulating factor (GM-CSF), and tumor necrosis factor (TNF). Why there is an increased incidence of this inflammatory late-stage complication in select young individuals and more frequently in patients who are elderly and in those with comorbidities is poorly understood. Interestingly though, 30% of individuals succumbing to H1N1 were found to carry single copies of genes commonly encountered in patients with HLH, suggesting a link between immune predisposition to sHLH and outcome.

We can also postulate that the chronic low-grade inflammation and an increase in self-reactivity that characterize the aging immune system also may be contributory. Importantly, recent studies have demonstrated that immunologic aging proceeds at different rates in different individuals and thus, mere chronologic age is, not surprisingly, a relatively crude predictor of COVID-19 progression.

From a therapeutic perspective, there is a clear need for an effective antiviral agent that can prevent viral infection in exposed individuals and limit tissue damage in those with established disease (stage 1 and 2). In stage 3, in the absence of any effective antiviral therapy, we are relegated to supportive care. It is at this stage that the experimental use of agents designed to limit tissue damage driven by uncontrolled inflammation is being investigated. Given the similarities to other hypercytokinemic states, a variety of nonspecific immunosuppressive strategies are needed, such as glucocorticoids, hydroxychloroquine, colchicine, and Janus kinase inhibitors, as well as a number of targeted therapies directed at pivotal cytokines. For now, the experience with such agents largely consists of anecdotal case reports and small clinical trials.

As of this writing, more than 270 clinical trials of various therapeutics for COVID-19 are registered at clinicaltrials.gov. A number of agents have been proposed or are in use, including anti-IL-1, anti-GM-CSF, anti-TNF, and Janus kinase inhibitors. Among these therapies, agents targeting IL-6 have generated the greatest enthusiasm. Two such agents (tocilizumab and sarilumab) are already approved by regulatory authorities and have demonstrated efficacy in randomized controlled trials.

IL-6 is a pleomorphic cytokine produced by both hematopoietic and viscerosomatic cells with far-reaching effects on immune function and diverse nonimmune physiologic processes. It is a key upstream driver of inflammatory pathways and has been successfully targeted therapeutically. IL-6 also has been shown to be a predictor of respiratory failure. Targeting IL-6 with tocilizumab is now indicated for treatment of cytokine storm accompanying CAR-T cell therapy. Clinical support for such studies has come from a variety of sources, including anecdotes from now widespread use of off-label tocilizumab, case reports, and small series where rapid reversal of laboratory and clinical parameters have been reported. Balancing enthusiasm for such a strategy is the known pivotal role of IL-6 in host defense, particularly in defense against respiratory viruses.

Above all, there are serious considerations in the timing of therapy. Administering treatment too early may compromise antiviral immunity, while waiting too long may risk irreversible organ damage. The phase 3 randomized controlled trial of tocilizumab (NCT04320615) and the phase 2/3 randomized controlled trial of sarilumab (NCT04315298) are projected to be complete within a number of months. Other novel therapies used alone or in combination include targeting IL-1, GM-CSF, granulocyte-colony stimulating factor, and Janus kinase. These have been reviewed or mentioned in several excellent narrative reviews.
REFERENCES

1. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol 2020 Mar 27 doi: 10.1001/jamacardio.2020.1286 [Epub ahead of print]

2. Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol 2020; 92(4):424–342. doi: 10.1002/jmv.25685

3. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. NEJM 2020; 382(10):970–971. doi: 10.1056/NEJMc2001468.

4. Joynt GM, Wu WK. Understanding COVID-19: what does viral RNA load really mean? Lancet Infect Dis 2020 Mar 27 pii: S1473-3099(20)30237-1. doi: 10.1016/S1473-3099(20)30237-1 [Epub ahead of print]

5. McGonagle D, Sharif K, O’Regan A, Bridgewood C. Interleukin-6 use in COVID-19 pneumonia related macrophage activation syndrome. Autoimmun Rev 2020 Apr 3:102537. doi: 10.1016/j.autrev.2020.102537 [Epub ahead of print]

6. Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol 2016; 12(5):259–268.

7. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395(10229):1033–1034. doi: 10.1016/S0140-6736(20)30628-0

8. Schulert GS, Zhang M, Fall N, et al. Whole-Exome Sequencing Reveals Mutations in Genes Linked to Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome in Fatal Cases of H1N1 Influenza. J Infect Dis 2016; 213(7):1180–1188. doi: 10.1093/infdis/jiv550

9. Alpert A, Pickman Y, Leipold M, et al. A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring. Nat Med 2019; 25(3):487–495. doi: 10.1038/s41591-019-0381-y

10. Ceribelli A, Motta F, De Santis M, et al. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy. J Autoimmun Volume 109, May 2020, 102442. doi.org/10.1016/j.jaut.2020.102442

11. Calabrese LH, Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol 2014; 10(12):720–727. doi: 10.1038/nrrheum.2014.127

12. Chen H, Wang F, Zhang P, et al. Management of cytokine release syndrome related to CAR-T cell therapy. Front Med 2019; 13(5):610–617. doi: 10.1007/s11684-019-0714-8

13. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents 2020 March 29:105954. doi: 10.1016/j.ijantimicag.2020.105954 [Epub ahead of print]

14. Rose-John S, Winthrop K, Calabrese L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat Rev Rheumatol 2017; 13(7):399–409. doi: 10.1038/nrrheum.2017.83
Cytokines and the still-baffling clinical biology of COVID-19

Although it seems like forever, we are only months into the COVID-19 pandemic, so it should really be no surprise that there are huge gaps in our understanding of the infection and its treatment. It took decades before we developed effective therapies for HIV, hepatitis B, and non-A non-B hepatitis. But this is different. It feels different. It was on us like a tidal wave, and we are now inundated with new data 24/7. Clinical descriptions of new syndromes linked to coronavirus infection and results of small randomized and larger observational studies appear online ahead of print, and alerts are forwarded to our inboxes in a constant stream, not to mention what we hear in the nightly news. Every medical center seems to be scrambling to conduct emergent clinical trials comparing novel treatments with “usual care,” but “usual care” of COVID-19 patients is also changing at a rapid pace.

With all this information, it seems we should know more than we do about how to manage the very sick. But it even in a pandemic affecting such a large number of patients in a short window of time, with many of them experiencing measurable outcome events, well-done randomized treatment trials take time to orchestrate and complete. When morbidity and mortality of hospitalized patients is high, with no known effective therapy, the usual care of patients will likely include multiple unproven medications in an attempt to turn the tide of their infection. This can dramatically complicate the analysis of observational studies. Plus, this virus drives a complicated pathobiology.

The clinical expression and course of COVID-19 are pleomorphic and, thus far, are not easily predicted. There are asymptomatic infected individuals who are nonetheless shedding virus, and presymptomatic individuals seemingly even more infective. Most patients experience a mild to modest illness with some combination of fatigue, gastrointestinal symptoms, anosmia, and respiratory symptoms. But some, perhaps after 5 to 10 days, have a second phase of illness characterized by markedly worsened respiratory symptoms due to severe and progressive viral pneumonia. And within this latter group, some experience a dramatic clinical downturn with variable cardiopulmonary collapse, high fevers, and hypercoagulability associated with laboratory markers consistent with what has been called cytokine storm, macrophage activation syndrome (MAS), or in some other settings, hemophagocytic lymphohistocytosis (HLH). The similarity to these latter syndromes, which often respond to agents directed against the cytokines interleukin 1 (IL-1) (anakinra, canakinumab) or interleukin 6 (IL-6) (tocilizumab, sarilumab), has led to empiric use of these agents and to the initiation of multiple formal clinical trials, as discussed by Dr. Len Calabrese in this issue of the Journal (page 389).

But it is not as simple as patients experiencing cytokine storm just having worse disease, characterized by immune overreactivity, which needs to be quelled by blocking the culprit immune hormone. The primary culprit contributing to the progressive lung dysfunction and damage is not certain. Is it all immune damage? Or is the contin-
ued persistence of coronavirus playing a direct or indirect role through continued activation of primordial components of the immune system? And is the hyperinflammatory response the body’s last-ditch effort at controlling the virus, in which case blocking it might (in the absence of an effective antiviral therapy) be counterproductive? Hence the need for well-done, controlled, and randomized clinical trials.

The respective significance of active viral infection and replication vs effects of ultra-high levels of inflammatory mediators (IL-1, IL-6, granulocyte-macrophage colony-stimulating factor) on lung damage and multisystem failure remains to be delineated. Elevated levels of IL-6 and downstream markers of cytokine effects (eg, ferritin) have been associated with death, but this association doesn’t prove that it is not the persistence of viral replication and viral products that are in fact contributing to the ongoing elaboration of these cytokines as well as to direct damage to lung tissue.

The biology is complicated. This novel coronavirus has been shown to increase synthesis of IL-1 by stimulating its precursor pro-IL-1 as well as activating the intracellular inflammasome cascade that cleaves active IL-1 from its precursor. Additionally, there are studies that indicate the virus can antagonize the initial host antiviral mechanisms involving interferon generation and natural killer cell-mediated destruction of viral infected cells, resulting in persistence of replicating virus. This latter effect can mimic the rare genetically influenced primary HLH syndromes. Thus, blocking specific cytokines may not be sufficient therapy, unless the virus itself can also be eliminated.

Adding to this complexity, there are studies demonstrating that IL-6 can play an important antiviral role and also can be a positive influence on repair and remodeling following experimental inflammatory lung injury induced in animals by endotoxin or bleomycin.

A lack of an answer to how best to treat patients with severe COVID-19 is not the same as having a lack of information. The latter continues to grow, the former will hopefully follow. Certainly, identifying a potent antiviral agent will help enormously, and I’d expect an antiviral will work synergistically with anticytokine strategies in patients with severe disease. In the meantime, we await clinical results and biochemical analyses from the several prospective trials under way, while wading through the minefields of many well-intentioned but compromised, complicated, and hard-to-interpret observational studies.

If after reading the Calabrese article you are interested in reading more about the fascinating biology of the immune response to this virus that is so rapidly unfolding, I refer you to 2 other well-referenced reviews, and more articles about COVID-19 in general are available at our COVID-19 Curbside Consults section at www.ccjm.org.

BRIAN F. MANDELL, MD, PhD
Editor in Chief

1. Zhong J, Tang J, Ye C, Dong L. The immunology of COVID-19: is immune modulation an option for treatment? Lancet Rheumatol 2020 May 20. doi:10.1016/s2665-9913(20)30120-x
2. McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev 2020; 19(6):102537. doi:10.1016/j.autrev.2020.102537